Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab

Adalimumab dose escalation is an effective and well-tolerated therapeutic option in patients with secondary loss of response. A 40 mg every week optimized regimen was predictive of a response to ADA dose escalation.